Alkyl Amines Chemicals Ltd
Incorporated in 1979 by Mr Yogesh Kothari, Alkyl Amines is a leading manufacturer of aliphatic amines in India. Aliphatic amines are products derived from Ammonia (NH3) by displacement of H2 in the Ammonia molecule by other radicals (R) such as Methyl, Ethyl and Propyl.
- Market Cap ₹ 9,136 Cr.
- Current Price ₹ 1,790
- High / Low ₹ 2,499 / 1,607
- Stock P/E 48.2
- Book Value ₹ 105
- Dividend Yield 0.56 %
- ROCE 41.3 %
- ROE 41.4 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company has delivered good profit growth of 33.3% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 31.6%
- Company has been maintaining a healthy dividend payout of 20.3%
Cons
- Stock is trading at 17.0 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Chemicals Industry: Chemicals
Part of BSE 250 SmallCap Index BSE Commodities BSE Allcap Nifty 500 Nifty Total Market
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
197 | 214 | 236 | 288 | 366 | 446 | 476 | 484 | 501 | 616 | 846 | 993 | |
175 | 183 | 205 | 245 | 308 | 361 | 390 | 393 | 405 | 499 | 682 | 736 | |
Operating Profit | 21 | 32 | 31 | 42 | 58 | 85 | 87 | 91 | 95 | 118 | 164 | 257 |
OPM % | 11% | 15% | 13% | 15% | 16% | 19% | 18% | 19% | 19% | 19% | 19% | 26% |
6 | 6 | 2 | 3 | 1 | 2 | 2 | 3 | 3 | 4 | 6 | 26 | |
Interest | 12 | 12 | 10 | 12 | 13 | 12 | 10 | 8 | 8 | 8 | 15 | 10 |
Depreciation | 7 | 9 | 9 | 9 | 10 | 10 | 11 | 13 | 14 | 16 | 23 | 27 |
Profit before tax | 8 | 18 | 14 | 24 | 36 | 65 | 67 | 73 | 75 | 97 | 133 | 246 |
Tax % | 33% | 28% | 24% | 27% | 33% | 33% | 32% | 31% | 31% | 32% | 35% | 18% |
6 | 13 | 14 | 18 | 24 | 43 | 45 | 50 | 52 | 66 | 86 | 201 | |
EPS in Rs | 1.10 | 2.51 | 2.74 | 3.45 | 4.75 | 8.48 | 8.85 | 9.81 | 10.16 | 12.94 | 16.88 | 39.47 |
Dividend Payout % | 36% | 24% | 22% | 23% | 21% | 19% | 18% | 41% | 20% | 22% | 19% | 20% |
Compounded Sales Growth | |
---|---|
10 Years: | 17% |
5 Years: | 16% |
3 Years: | 26% |
TTM: | 17% |
Compounded Profit Growth | |
---|---|
10 Years: | 31% |
5 Years: | 33% |
3 Years: | 54% |
TTM: | 120% |
Stock Price CAGR | |
---|---|
10 Years: | 30% |
5 Years: | 25% |
3 Years: | -17% |
1 Year: | -21% |
Return on Equity | |
---|---|
10 Years: | 28% |
5 Years: | 29% |
3 Years: | 32% |
Last Year: | 41% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Reserves | 56 | 64 | 75 | 88 | 106 | 140 | 174 | 199 | 246 | 299 | 369 | 526 |
133 | 114 | 120 | 123 | 146 | 151 | 135 | 111 | 120 | 181 | 165 | 87 | |
54 | 51 | 52 | 60 | 78 | 98 | 93 | 95 | 147 | 159 | 218 | 160 | |
Total Liabilities | 254 | 238 | 258 | 282 | 341 | 398 | 412 | 416 | 522 | 649 | 763 | 783 |
103 | 98 | 98 | 122 | 126 | 155 | 151 | 187 | 220 | 355 | 376 | 423 | |
CWIP | 7 | 14 | 23 | 6 | 9 | 3 | 31 | 16 | 35 | 18 | 43 | 45 |
Investments | 4 | 6 | 10 | 10 | 10 | 10 | 10 | 10 | 12 | 13 | 16 | 0 |
139 | 121 | 126 | 144 | 195 | 230 | 220 | 203 | 256 | 262 | 328 | 315 | |
Total Assets | 254 | 238 | 258 | 282 | 341 | 398 | 412 | 416 | 522 | 649 | 763 | 783 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
22 | 43 | 24 | 36 | 22 | 47 | 61 | 101 | 63 | 102 | 144 | 188 | |
-22 | -10 | -17 | -19 | -27 | -27 | -31 | -35 | -65 | -132 | -67 | -41 | |
3 | -35 | -9 | -13 | 5 | -13 | -36 | -68 | -2 | 32 | -60 | -135 | |
Net Cash Flow | 3 | -2 | -2 | 4 | 0 | 7 | -6 | -2 | -3 | 2 | 17 | 12 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 70 | 66 | 73 | 77 | 76 | 73 | 76 | 68 | 71 | 73 | 66 | 60 |
Inventory Days | 261 | 180 | 166 | 124 | 132 | 126 | 105 | 92 | 165 | 99 | 88 | 67 |
Days Payable | 1 | 0 | 70 | 63 | 69 | 75 | 58 | 63 | 120 | 78 | 104 | 57 |
Cash Conversion Cycle | 329 | 246 | 170 | 137 | 139 | 124 | 123 | 96 | 116 | 94 | 51 | 71 |
Working Capital Days | 182 | 142 | 101 | 84 | 94 | 96 | 93 | 87 | 84 | 76 | 56 | 54 |
ROCE % | 11% | 15% | 12% | 17% | 20% | 28% | 25% | 25% | 24% | 25% | 28% | 41% |
Documents
Announcements
-
Integrated Filing (Financial)
24 Jan - Integrated financial results for Q3 and nine months ended December 31, 2024.
-
Opening Of Trading Window
24 Jan - Opening of trading window for designated persons.
-
Board Meeting Outcome for Financial Results - December 2024
24 Jan - Board approved unaudited financial results for Q3 2024.
-
Financial Results - December 2024
24 Jan - Board approved unaudited financial results for Q3 2024.
-
Board Meeting Intimation for Approval Of Unaudited Financial Results For Quarter And Nine Months Ended December 31, 2024
10 Jan - Board meeting to approve unaudited financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024TranscriptPPT
-
May 2024TranscriptPPTREC
-
May 2024TranscriptNotesPPTREC
-
Nov 2023TranscriptPPTREC
-
May 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Jul 2020TranscriptPPT
-
Nov 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Jun 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Jun 2017TranscriptPPT
-
May 2016TranscriptPPT
Business Leadership
The co. offers 100+ products, it is a global leader in many products including acetonitrile, DEHA, DMA-HCLA, and Triethylamine. [1]